Flt3 ligand (FL) and its influence on immune reactivity

Cytokine

Volumn 12, Issue 2, 2000, Pages 87-100

  Antonysamy, Mary A ^a   Thomson, Angus W ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Flt3 ligand; Haematopoiesis; Immune reactivity

Indexed keywords

FLT3 LIGAND;

ALLOIMMUNITY; B LYMPHOCYTE; DENDRITIC CELL; GENE THERAPY; HEMATOPOIESIS; IMMUNOBIOLOGY; MOLECULAR CLONING; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

EID: 0033934787     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0540     Document Type: Article

References (119)

1. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 57:1988;443-478.
2. Rosnet O, Mattei MG, Marchetto S, Birnbaum D. Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics. 9:1991;380-385.
3. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSFIR family. Oncogene. 6:1991;1641-1650.
4. Rosnet O, Schiff C, Pebusque M-J, Marchetto S, Tonnelle C, Tolron Y, Birg F, Birnbaum D. Human FLT31FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 82:1993;1110-1119.
5. Matthews W, Jordan CT, Wiegand GW, Pardoll D, Lemischka IR. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65:1991;1143-1152.
6. Lyman SD, James L, Zappone J, Sleath PR, Beckmann MP, Bird T. Characterization of the protein encoded by the fIt3 (flk2) receptor-like tyrosine kinase gene. Oncogene. 8:1993;815-822.
7. Dosil M, Wang S, Lemischka IR. Mitogenic signaling and substrate specificity of the flk2/flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol. 13:1993;6572-6585.
8. Birg F, Rosnet O, Carbuccia N, Birnbaum D. The expression of FMS, KIT and FLT3 in hematopoietic malignancies. Leuk Lymphoma. 13:1994;223-227.
9. Agnes F, Shamoon B, Dina C, Rosnet O, Birnbaum D, Galibert F. Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. Gene. 145:1994;283-288.
10. Lavagna C, Marchetto S, Birnbaum D, Rosnet O. Identification and characterization of a functional murine FLT3 isoform produced by exon skipping. J Biol Chem. 270:1995;3165-3171.
11. +human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A. 91:1994;459-463.
12. Imbert A, Rosnet O, Marchetto S, Ollendorff V, Birnbaum D, Pebusque MJ. Characterization of a yeast artificial chromosome from human chromosome band 13q12 containing the FLTI and FLT3 receptor-type tyrosine kinase genes. Cytogenet Cell Genet. 67:1994;175-177.
13. Lyman SD, James L, Vanden Bos T, de Vries P, Brasel X, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FF, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 75:1993;1157-1167.
14. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J, Luh J, Duda G, Martina N, Peterson D, Menon S, Shanafelt A, Muench M, Kelner G, Namikawa R, Rennick D, Roncarolo MG, Zlotnick A, Rosnet O, Dubreuil P, Birnbaum D, Lee F. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoletic stem cells and is encoded by variant RNAs. Nature. 368:1994;643-648.
15. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, Downey H, Splett RR, Beckmann MP, McKenna HJ. Cloning of the human homologue of the murine f1t3 ligand: a growth factor for early hematopoietic progenitor cells. Blood. 83:1994;2795-2801.
16. Lyman SD, Stocking K, Davison B, Fletcher F, Johnson L, Escobar S. Structural analysis of human and murine fIt3 ligand genomic loci. Oncogene. 11:1995;1165-1172.
17. Lyman SD, Brasel K, Rousseau AM, Williams DE. The f1t3 ligand: a hematopoietic stem cell factor whose activities are distinct from steel factor. Stem Cells. 12:1994;99-107.
18. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS, Jenkins NA, Belmont JW, Davison BL. Identification of soluble and membrane-bound isoforms of the murine f1t3 ligand generated by alternative splicing of mRNAs. Oncogene. 10:1995;149-157.
19. McClanahan T, Culpepper J, Campbell D, Wagner J, FranzBacon K, Mattson J, Tsai S, Luh J, Guimaraes MJ, Mattei MG, Rosnet O, Birnbaum D, Hannum CH. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood. 88:1996;3371-3382.
20. Rosnet O, Stephenson D, Mattei MG, Marchetto S, Shibuya M, Chapman VM, Birnbaum D. Close physical linkage of the flt1 and flt3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene. 8:1993;173-179.
21. Brasel K, Escobar S, Anderberg R, de Vries P, Gruss H-J, Lyman SD. Expression of the flt3 receptor and its ligand on hematopoietic cells. Leukemia. 9:1995;1212-1218.
22. deLapeyriere O, Naquet P, Planche J, Marchetto S, Rottapel R, Gambarelli D, Rosnet O, Birnbaum D. Expression of Flt3 tyrosine kinase receptor gene in mouse hematopoietic and nervous tissues. Differentiation. 58:1995;351-359.
23. Rasko JEJ, Metcalf D, Rossner MT, Begley CG, Nicola NA. The flt3/flk-2 ligand: receptor distribution and action on murine haemopoietic cell survival and proliferation. Leukemia. 9:1995;2058-2066.
24. Ito A, Hirota S, Kitamura Y, Nomura S. Developmental expression of f1t3 mRNA in the mouse brain. J Mol Neurosci. 4:1993;235-243.
25. Wasserman R, Li Y-S, Hardy RR. Differential expression of the Blk and Ret tyrosine kinases during B lineage development is dependent on Ig rearrangement. J Immunol. 155:1995;644-651.
26. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 3:1995;147-161.
27. Zeigler FC, Bennett BD, Jordan CT, Spencer SD, Baumhueter S, Carroll KJ, Hooley J, Bauer K, Matthews W. Cellular and molecular characterization of the role of the FLK2/FLT-3 receptor tyrosine kinase in hematopoietic stem cells. Blood. 84:1994;2422-2430.
28. Rosnet O, Biffiring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, Arnoulet C, Chabannon C, Kanz L, Hannum C, Birnbaum D. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 10:1996;238-248.
29. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P, Vitelli L, Barberi T, Testa U, Lyman S. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood. 86:1995;1661-1670.
30. McKenna HJ, Miller RE, Brasel KE, Maraskovsky E, Maliszewski C, Pulendran B, Lynch D, Teepe M, Roux ER, Smith J, Williams DE, Lyman SD, Peschon JJ, Stocking K. Targeted disruption of the fIt3 ligand gene in mice affects multiple hematopoietic lineages, including natural killer cells, B lymphocytes, and dendritic cells. Blood. 88:1996;474a.
31. +hematopoietic progenitor cells. Blood. 86:1995;3413-3420.
32. +CD38 cells and maintains progenitor cells in vitro. Blood. 87:1996;3563-3570.
33. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol. 23:1995;1121-1129.
34. +bone marrow progenitor cells - in vitro. Blood. 87:1996;1317-1325.
35. Koller MR, Oxender M, Brott DA, Palsson BO. Flt3 ligand is more potent than c-kit ligand for the synergistic stimulation of ex vivo hematopoietic cell expansion. J Hematother. 5:1996;449-459.
36. Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood. 85:1995;1762-1768.
37. Hudak S, Hunte B, Culpepper J, Menon S, Hannum C, ThompsonSnipes L, Rennick D. FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. Blood. 85:1995;2747-2755.
38. Jacobsen SEW, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL12, and other hematopoietic growth factors. J Exp Med. 181:1995;1357-1363.
39. Jacobsen SEW, Veiby OP, Myklebust J, Okkenhaug C, Lyman SD. Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-β and tumor necrosis factor-α Blood. 87:1996;5016-5026.
40. Ohishi K, Katayama N, Itoh R, Mahmud N, Miwa H, Kita K, Minami N, Shirakawa S, Lyman SD, Shiku H. Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-β Blood. 87:1996;1718-1727.
41. +hematopoietic progenitors elicited from human fetal liver, umbilical cord blood, bone marrow, and mobilized peripheral blood. J Hematother. 5:1996;655-662.
42. -) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin. J Exp Med. 183:1996;2551-2558.
43. Ramsfjell V, Borge OJ, Cardier J, Murphy MJ Jr, Lyman SD, Jacobsen SEW. Thrombopoietin, but not erythropoietin, directly stimulates multilineage growth of primitive murine bone marrow progenitor cells in synergy with early acting cytokines: distinct interactions with the ligands for c-kit and FLT3. Blood. 88:1997;4481-4492.
44. Lyman SD, Maraskovsky E, McKenna HJ. Flt3 ligand. Thomson AW. The Cytokine Handbook. 1998;727-752 Academic Press, San Diego.
45. Hjertson M, Sundstrom C, Lyman SD, Nilsson K, Nilsson G. Stem cell factor, but not flt3 ligand, induces differentiation and activation of human mast cells. Exp Hematol. 24:1996;748-754.
46. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD. Hematologic effects of fIt3 ligand in vivo in mice. Blood. 88:1996;2004-2012.
47. Lyman SD, Seaberg M, Hanna R, Zappone J, Brasel K, Abkowitz JL, Prchal JT, Schultz JC, Shahidi NT. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 86:1995;4091-4096.
48. Wodnar-Fihpowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic: progenitor cell function in multilineage bone marrow failure. Blood. 88:1996;4493-4499.
49. +cells in vitro. Nature Med. 2:1996;46-51.
50. Moore TA, Zlotnik A. Differential effects of flk2/flt3 ligand and stem cell factor on murine thymic progenitor cells. J Immunol. 158:1997;4187-4193.
51. Hunte BE, Hudak S, Campbell D, Xu Y, Rennick D. flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors. J Immunol. 156:1996;489-496.
52. Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol. 26:1996;1504-1510.
53. Namikawa R, Muench MO, de Vries JE, Roncarolo MG. The FLK2/FLT3 ligand synergizes with interleukin-7 in promoting stromal-cell-independent expansion and differentiation of human fetal pro-B cells in vitro. Blood. 87:1996;1881-1890.
54. -cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J Exp Med. 186:1997;1609-1614.
55. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL. Expansion of functional natural killer cells in multiple tissue compartments of mice treated with flt3-Ligand: Implications for anti-cancer and anti-viral therapy. J Immunol. 161:1998;2817-2824.
56. +bone marrow precursors cultured with c-kit ligand, granulocyte macrophage colony stimulating factor, and TNF-α J Immunol. 154:1995;5851-5861.
57. Wu L, Li C-L, Shortman K. Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J Exp Med. 184:1996;903-911.
58. Ardavin C, Wu L, Li C-L, Shortman K. Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature. 362:1993;761-763.
59. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 3:1995;459-473.
60. Inaba K, Inaba M, Deguchi M, Hagi K, Yasumizu R, Ikehara S, Muramatsu S, Steinman RM. Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci U S A. 90:1993;3038-3042.
61. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 9:1991;271-296.
62. Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, Starzl TE. Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells. 13:1995;622-639.
63. -) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation. 60:1995;1539-1545.
64. -) prolong cardiac allograft survival in non-immunosuppressed recipients. Transplantation. 62:1996;659-665.
65. Rastellini C, Lu L, Ricordi C, Starzl TE, Rao AS, Thomson AW. GM-CSF stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation. 60:1995;1366-1370.
66. Matzinger P, Guerder S. Does T-cell tolerance require a dedicated antigen presenting cell? Nature. 338:1989;74-76.
67. Mazda O, Watanabe Y, Gyotoku J-I, Katsura Y. Requirement of dendritic cells and B cells in the clonal deletion of Mls-reactive T cells in the thymus. J Exp Med. 173:1991;539-547.
68. Suss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med. 183:1996;1789-1796.
69. Cella M, Scheidegger D, Palmer-Lehmann, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin 12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 184:1996;747-752.
70. Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL. Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med. 182:1995;357-366.
71. Lu L, Bonham AC, Chambers FG, Watkins SC, Hoffman RA, Simmons RL, Thomson AW. Induction of nitric oxide synthase in mouse dendritic cells by IFNγ, endotoxin and interaction with allogeneic T cells. Nitric oxide production is associated with dendritic cell apoptosis. J Immunol. 157:1996;3577-3586.
72. Bonham CA, Lu L, Banas RA, Fontes P, Rao AS, Zeevi A, Thomson AW. TGF-β1 pretreatment impairs the allostimulatory function of human bone marrow-derived antigen-presenting cells for both naïve and primed T cells. Tranplant Immunol. 4:1996;186-191.
73. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation. 66:1998;1567-1574.
74. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 184:1996;1953-1962.
75. Drakes ML, Lu L, Subbotin VM, Thomson AW. In vivo administration of flt3 ligand markedly stimulates generation of dendritic cell progenitors from mouse liver. J Immunol. 159:1997;4268-4278.
76. +blood progenitors for anticancer therapy. Exp Hematol. 23:1995;1463-1471.
77. Lebsack ME, Maraskovsky E, Roux E, Teepe M, Hirschstein D, Hoek J, McKenna HJ, Maliszewski C, Caron D. Increased circulatory dendritic cells in healthy human volunteers following administration of flt3 ligand alone or in combination with GM-CSF or G-CSF. Blood. 92:1998;507a.
78. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, Ramos H, Todo S, Tzakis A, Fung JJ, Nalesnik M, Rudert WA, Kocova M. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology. 17:1993;1127-1152.
79. Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism and allograft survival. Immunol Today. 17:1996;577-584.
80. Murase N, Starzl TE, Tanabe M, Fujisaki S, Miyazawa H, Ye Q, Delaney CP, Fung JJ, Demetris AJ. Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to Brown Norway rats. Transplantation. 60:1995;158-171.
81. Khanna A, Thomson AW. Hematopoietic growth factors in transplantation: Biology and applications. Transplant Rev. 12:1998;121-139.
82. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LWM, Hardwick A, Moubayed M, Oldham F, Corringham RET, Ho AD. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood. 85:1995;275-282.
83. Roberts AW, Metcalf D. Granulocyte colony-stimulating factor induces selective elevations of progenitor cells in the peripheral blood of mice. Exp Hematol. 22:1994;1156-1163.
84. Brasel K, McKenna HJ, Charrier K, Morrissey P, Williams DE, Lyman SD. Mobilization of peripheral blood progenitor cells with Flt3 ligand. Blood. 86:1995;463a.
85. Fontes P, Rao AS, Demetris AJ, Zeevi A, Trucco M, Carroll P, Rybka W, Rudert WA, Ricordi C, Dodson F, Shapiro R, Tzakis A, Todo S, Abu-Elmagd K, Jordan M, Fung JJ, Starzl TE. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet. 344:1994;151-155.
86. Khanna A, Steptoe RJ, Antonysamy MA, Li W, Thomson AW. Donor bone marrow potentiates the effect of tacrolimus on non-vascularized heart allograft survival. Transplantation. 65:1998;479-485.
87. Garcia-Morales R, Esquenazi V, Zucker K, Gomez CI, Fuller L, Carreno M, Cirocco R, Alamo A, Karatzas T, Burke GW 3rd, Ciancio G, Temple D, Fernandez H, Ricodi C, Tzakis A, Miller J. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation. 62:1996;1149-1160.
88. Lu L, Rudert WA, Qian S, McCaslin D, Fu F, Rao AS, Trucco M, Fung JJ, Starzl TE, Thomson AW. Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med. 182:1995;379-387.
89. Thomson AW, Lu L, Wan Y, Qian S, Larsen CP, Starzl TE. Identification of donor-derived dendritic cell progenitors in bone marrow of spontaneously tolerant liver allograft recipients. Transplantation. 60:1995;1555-1559.
90. Iyengar AR, Bonham CA, Antonysamy MA, Subbotin VM, Khanna A, Murase N, Rao AS, Starzl TE, Thomson AW. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by flt3 ligand and tacrolimus. Transplantation. 63:1997;1193-1199.
91. Antonysamy MA, Steptoe RJ, Khanna A, Rudert W, Subbotin VM, Thomson AW. Flt-3 L promotes microchimerism but can augment anti-donor immunity. J Immunol. 160:1998;4106-4113.
92. Khanna A, Antonysamy MA, Subbotin VM, Steptoe RJ, Li W, Rudert WA, Thomson AW. Impact of flt3 ligand on donor-derived antigen presenting cells and alloimmune reactivity in heart graft recipients given adjuvant donor bone marrow. Transplant Immunol. 6:1998;225-234.
93. Markees TG, Phillips NE, Gordon EJ, Noelle RJ, Maliszewski C, Mordes JP, Greiner DL, Rossini AA. Prolonged skin allograft survival in mice treated with flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Transplant Proc. 31:1999;884-885.
94. Gozzo J, Masli S, De Fazio S. Extension of graft survival with pulsed administration of donor dendritic cells. Transplant Proc. 31:1999;1196.
95. Lu L, Li W, Fu F, Chambers FG, Qian S, Fung JJ, Thomson AW. Blockade of the CD40-CD40L pathway potentiates the capacity of donor-derived DC progenitors to induce long-term cardiac allograft survival. Transplantation. 64:1997;1808-1815.
96. Terakura M, Murase N, Demetris AJ, Ye Q, Thomson AW, Starzl TE. Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. Transplantation. 66:1998;350-357.
97. Neipp M, Zorina T, Domenick MA, Exner BG, Ilstad ST. Effect of flt3 ligand and granulocyte colony-stimulating factor on expansion and mobilization of facilitating cells and hematopoietic stem cells in mice: Kinetics and repopulating potential. Blood. 92:1998;3177-3188.
98. Steptoe RJ, Fu F, Li W, Drakes ML, Lu L, Demetris AJ, Qian S, McKenna HJ, Thomson AW. Augmentation of dendritic cells in murine organ donors by flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol. 159:1997;5483-5491.
99. Qian S, Lu L, Fu F, Li W, Pan F, Steptoe RJ, Chambers FG, Starzl TE, Fung JJ, Thomson AW. Donor pretreatment with flt3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Tranplantation. 65:1998;1590-1598.
100. Pulendran B, Smith JL, Jenkins M, Schoenborn M, Maraskovsky E, Maliszewski CR. Prevention of peripheral tolerance by a dendritic cell growth factor: Flt3 ligand as an adjuvant. J Exp Med. 188:1998;2075-2082.
101. Viney JL, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 160:1998;5815-5825.
102. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A. 96:1999;1036-1041.
103. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, Moore MA, Crystal G. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med. 186:1997;1247-1256.
104. Condon C, Watkins SC, Celluzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2:1996;1122-1128.
105. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1:1995;1297-1302.
106. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med. 183:1996;7-11.
107. Wong C, Morse M, Nair SK. Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. J Immunother. 21:1998;32-40.
108. Celluzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol. 160:1998;3081-3085.
109. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4:1998;594-600.
110. Barratt-Boyes SM, Kao H, Finn OJ. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J Immunother. 21:1998;142-148.
111. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 162:1999;168-175.
112. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL. Flt3 ligand induces tumor regression and anti-tumor responses in vivo. Nature Med. 3:1997;625-631.
113. Peron J-M, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. Flt3-ligand administration inhibits liver metastases: role of NK cells. J Immunol. 161:1998;6164-6170.
114. Pawlowska AB, Hashino S, McKenna HJ, Taylor PA, Blazar BR. The in vivo infusion of either flt3 ligand protein or ex vivo generated BM-derived dendritic cells pulsed with leukemia antigen(s) protect naïve or syngeneic BMT mice from a lethal dose of acute myeloid leukemia cells. Blood. 92:1998;721a.
115. Elwood NJ, Zogos H, Willson T, Begley CG. Retroviral transduction of human progenitor cells: use of granulocyte colony stimulating factor plus stem cell factor to mobilize progenitor cells in vivo and stimulation by Flt3/Flk2 ligand in vitro. Blood. 88:1996;4452-4462.
116. +progenitors to sustain long-term hematopoiesis in immunodeficient mice after ex vivo retroviral-mediated transduction. Blood. 89:1997;446-456.
117. +T cell help to elicit protective and therapeutic antitumor immunity. J Immunol. 162:1999;144-151.
118. Braun SE, Aronica SM, Ge Y, Takahira H, Etienne-Julan M, Lu L, Minden MD, Lyman SD, Broxmeyer HE. Retroviral mediated gene transfer enhances proliferation and MAP kinase activity of AML5 cells. Exp Hematol. 25:1997;51-56.
119. Chen K, Braun S, Lyman S, Fan Y, Traycoff M, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K. Antitumor activity and immunotherapeutic properties of flt3L in a murine breast cancer model. Cancer Res. 57:1997;3511-3516.